Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 63

Sort by

Sort Order Select

Meeting Abstracts

1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

MAGNUS F.G. GRØNDAHL, CAROLINE T. JUEL, ASGER LUND, SOFIE HAEDERSDAL, MARIA M. ANDERSEN, JENS S. SVENNINGSEN, MATTHEW GILLUM, BOLETTE HARTMANN, JENS J. HOLST, TINA VILSBØLL, FILIP K. KNOP

Diabetes 2023;72(Supplement_1):1651-P

https://doi.org/10.2337/db23-1651-P

Published: 20 June 2023

View article titled, 1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

Meeting Abstracts

1559-P: Glucagon Receptor–Mediated Improvements in Glycemia Are Dependent on Agonist Pharmacodynamics

SHELLY NASON, TEAYOUN KIM, JESSICA ANTIPENKO, BIN YANG, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2023;72(Supplement_1):1559-P

https://doi.org/10.2337/db23-1559-P

Published: 20 June 2023

View article titled, 1559-P: Glucagon Receptor–Mediated Improvements in Glycemia Are Dependent on Agonist Pharmacodynamics

Meeting Abstracts

72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD

DENNIS TO, JAEHEE SHIN, SUBBU KARANTH, YEN-HUEI LIN, SVETLANA SOSNOVTSEVA, ADAM C. BELL

Diabetes 2023;72(Supplement_1):72-LB

https://doi.org/10.2337/db23-72-LB

Published: 20 June 2023

View article titled, 72-LB: DD01, a Novel Once-Weekly Dual GLP-1/Glucagon Receptor Agonist, Improves Metabolic Health and Achieves Rapid, Clinically Significant Reductions in Hepatic Steatosis following Only Four Weeks of Treatment and without the Need for Significant Weight Loss in Overweight/Diabetic Subjects with NAFLD

Meeting Abstracts

267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial

SCHAFER C. BOEDER, MELISSA J. LE ROUX, ERIN R. GIOVANNETTI, ADRIENNE ARMSTRONG, LESLIE CARTER, ROBERT L. THOMAS, JUSTIN M. GREGORY, JEREMY PETTUS

Diabetes 2023;72(Supplement_1):267-OR

https://doi.org/10.2337/db23-267-OR

Published: 20 June 2023

View article titled, 267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial

Journal Articles

In This Issue of Diabetes

Max Bingham, PhD

Diabetes 2023;72(5):545–546

https://doi.org/10.2337/db23-ti05

Published: 20 April 2023

View article titled, In This Issue of <em>Diabetes</em>

Journal Articles

In This Issue of Diabetes

Max Bingham, PhD

Diabetes 2022;71(10):2065–2066

https://doi.org/10.2337/db22-ti10

Published: 12 September 2022

View article titled, In This Issue of <em>Diabetes</em>

Journal Articles

Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

Teayoun Kim, Shelly Nason, Jessica Antipenko, Brian Finan, Anath Shalev, Richard DiMarchi, Kirk M. Habegger

Diabetes 2022;71(10):2123–2135

https://doi.org/10.2337/db21-1018

Published: 25 July 2022

View article titled, Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

Meeting Abstracts

1332-P: Increased and Decreased Glucagon Receptor Signaling Respectively Enhances and Impairs Triglyceride Metabolism Acutely and Chronically

KATRINE D. GALSGAARD, EMILIE E. CHRISTENSEN, ANNA B. BOMHOLT, JENNA HUNT, THOMAS KRUSE, JESPER F. LAU, CHRISTINA CHRISTOFFERSEN, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN

Diabetes 2022;71(Supplement_1):1332-P

https://doi.org/10.2337/db22-1332-P

Published: 01 June 2022

View article titled, 1332-P: Increased and Decreased Glucagon Receptor Signaling Respectively Enhances and Impairs Triglyceride Metabolism Acutely and Chronically

Meeting Abstracts

197-OR: Glucagon Receptor Agonism Stimulates Time-Dependent Glycemic Regulation

SHELLY NASON, TEAYOUN KIM, JESSICA P. ANTIPENKO, BRIAN FINAN, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2022;71(Supplement_1):197-OR

https://doi.org/10.2337/db22-197-OR

Published: 01 June 2022

View article titled, 197-OR: Glucagon Receptor Agonism Stimulates Time-Dependent Glycemic Regulation

Meeting Abstracts

230-OR: Hepatic TORC2 Signaling Facilitates Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

TEAYOUN KIM, SHELLY NASON, JESSICA P. ANTIPENKO, BRIAN FINAN, ANATH SHALEV, RICHARD DIMARCHI, KIRK M. HABEGGER

Diabetes 2022;71(Supplement_1):230-OR

https://doi.org/10.2337/db22-230-OR

Published: 01 June 2022

View article titled, 230-OR: Hepatic TORC2 Signaling Facilitates Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

Meeting Abstracts

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

SHWETA URVA, MEI TENG LOH, TAMER COSKUN, YU DU, CHARLES BENSON, CORINA LOGHIN, AXEL HAUPT, ZVONKO MILICEVIC

Diabetes 2022;71(Supplement_1):340-OR

https://doi.org/10.2337/db22-340-OR

Published: 01 June 2022

View article titled, 340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

Meeting Abstracts

236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

JEREMY PETTUS, SCHAFER C. BOEDER, MARK P. CHRISTIANSEN, DOUGLAS S. DENHAM, TIMOTHY S. BAILEY, HALIS K. AKTURK, LESLIE J. KLAFF, JULIO ROSENSTOCK, MICKIE H.M. CHENG, BRUCE W. BODE, EDGAR D. BAUTISTA, HAI YAN, DUNG THAI, SATISH K. GARG, SAMUEL KLEIN

Diabetes 2021;70(Supplement_1):236-OR

https://doi.org/10.2337/db21-236-OR

Published: 01 June 2021

View article titled, 236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Meeting Abstracts

667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity

HONGWEI JIANG, PEI AN, HELENA DENG, LI LI, LIQI FENG, QINGYANG MA, LEI QIAN, LINONG JI

Diabetes 2021;70(Supplement_1):667-P

https://doi.org/10.2337/db21-667-P

Published: 01 June 2021

View article titled, 667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity

Meeting Abstracts

674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

VICTORIA E. PARKER, THUONG HOANG, HEIKE SCHLICHTHAAR, FRASER W. GIBB, BARBARA WENZEL, MAXIMILIAN G. POSCH, YI-TING CHANG, MARCELLA PETRONE, LARS HANSEN, PHILIP AMBERY, HIDDO L. HEERSPINK, RORY J. MCCRIMMON, LUTZ JERMUTUS

Diabetes 2021;70(Supplement_1):674-P

https://doi.org/10.2337/db21-674-P

Published: 01 June 2021

View article titled, 674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

Meeting Abstracts

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

SHWETA URVA, YU DU, MELISSA K. THOMAS, ZVONKO MILICEVIC, TAMER COSKUN, CHARLES BENSON, CORINA LOGHIN

Diabetes 2021;70(Supplement_1):104-OR

https://doi.org/10.2337/db21-104-OR

Published: 01 June 2021

View article titled, 104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

Meeting Abstracts

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

XIAONA CUI, TIANJIAO WEI, JIN FENG, JIN YANG, HAI YAN, RUI WEI, TIANPEI HONG

Diabetes 2021;70(Supplement_1):115-LB

https://doi.org/10.2337/db21-115-LB

Published: 01 June 2021

View article titled, 115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

Journal Articles

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Sofie Hædersdal, Asger Lund, Elisabeth Nielsen-Hannerup, Henrik Maagensen, Gerrit van Hall, Jens J. Holst, Filip K. Knop, Tina Vilsbøll

Diabetes 2020;69(12):2619–2629

https://doi.org/10.2337/db20-0369

Published: 01 October 2020

View article titled, The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

Meeting Abstracts

255-OR: ADA Presidents’ Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets

KATIE C. COATE, ERICK SPEARS, CHUNHUA DAI, SCOTT WISNIEWSKI, GREG POFFENBERGER, LEONARD D. SHULTZ, DALE L. GREINER, DANIEL J. DRUCKER, HAI YAN, KYLE SLOOP, ALVIN C. POWERS, DANIELLE DEAN

Diabetes 2020;69(Supplement_1):255-OR

https://doi.org/10.2337/db20-255-OR

Published: 01 June 2020

View article titled, 255-OR: ADA Presidents’ Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets

Meeting Abstracts

1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice

JAMES L. TREVASKIS, JENNY NORLIN, DIEGO A. MIRANDA, JAMIE G. BATES, NORA E. ZOIS, SANNE VEIDAL, MICHAEL FEIGH, MARKUS LATTA

Diabetes 2020;69(Supplement_1):1813-P

https://doi.org/10.2337/db20-1813-P

Published: 01 June 2020

View article titled, 1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice

Meeting Abstracts

1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches

SASHA KJELDSEN, KATRINE D. GALSGAARD, MARIE WINTHER-SOERENSEN, REZA SERIZAWA, JENS PEDERSEN, CATHRINE ORSKOV, REIDAR ALBRECHTSEN, CHARLOTTE M. SORENSEN, LISE GLUUD, JENS J. HOLST, NICOLAI J. WEWER ALBRECHTSEN

Diabetes 2020;69(Supplement_1):1908-P

https://doi.org/10.2337/db20-1908-P

Published: 01 June 2020

View article titled, 1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches

NARROW

1651-P: Elevated FGF21 Levels after Total Pancreatectomy and in Response to Single-Dose Glucagon Receptor Antagonism in Humans

1559-P: Glucagon Receptor–Mediated Improvements in Glycemia Are Dependent on Agonist Pharmacodynamics

267-OR: ADA Presidents' Select Abstract: Combining an SGLT Inhibitor with a Glucagon Receptor Agonist (GRA) in Subjects with Type 1 Diabetes—A Randomized Clinical Trial

In This Issue of Diabetes

In This Issue of Diabetes

Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

1332-P: Increased and Decreased Glucagon Receptor Signaling Respectively Enhances and Impairs Triglyceride Metabolism Acutely and Chronically

197-OR: Glucagon Receptor Agonism Stimulates Time-Dependent Glycemic Regulation

230-OR: Hepatic TORC2 Signaling Facilitates Glucagon-Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice

340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment

236-OR: Volagidemab, a Human Glucagon Receptor Antagonist, Improves Glycemic Control in Subjects with Type 1 Diabetes (T1D): A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

667-P: IBI362 (LY3305677), a Weekly-Dose Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist, in Subjects with Overweight or Obesity

674-P: Efficacy and Safety of Cotadutide, a Dual GLP-1 and Glucagon Receptor Agonist in Patients with T2DM and DKD

104-OR: Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects

115-LB: Liver-Derived FGF21 Mediates the Promoting Effect of Glucagon Receptor Antagonism on Beta-Cell Regeneration in Type 2 Diabetic Mice

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

255-OR: ADA Presidents’ Select Abstract: Glucagon Receptor Antagonism Stimulates Beta-Cell Proliferation in Mouse and Human Islets

1813-P: Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice

1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only